1. Introduction
===============

Anterior uveitis (AU) is the most common pattern of uveitis, accounting for 50% to 92% of uveitis cases in western countries.^\[[@R1]--[@R3]\]^ A significant proportion of patients have no evidence of an underlying disorder and are labeled as idiopathic, but there is also an important percentage of patients with an associated systemic disorder such as spondyloarthritis (SpA).^\[[@R4]\]^

AU usually responds well to topical corticosteroids.^\[[@R5]\]^ However, there are cases, especially those associated with systemic disorders that may require additional drugs. For example, HLA-B27 AU, is typically more severe, recurrent, and associated with a higher incidence of ocular complications,^\[[@R6]\]^ including wide anterior and posterior synechiae, secondary glaucoma, and cystoid macular edema.^\[[@R7],[@R8]\]^ For these patients, periocular corticosteroid injection is an option as well as systemic corticosteroid therapy.^\[[@R9]\]^ Corticosteroids alone might help decrease ocular inflammation during exacerbations. However, they are not sufficient for many cases of chronic uveitis and do not prevent further relapses. Besides, long-term corticosteroid therapy also incurs significant risk of unacceptable adverse events (AE) like cushingoid changes, iatrogenic diabetes, osteoporosis, and hypercholesterolemia.^\[[@R10]\]^

On the other hand, immunomodulatory drugs have been widely used in patients with uveitis for decades. Classical immunomodulators such as salazopyrin (SSZ) or methotrexate (MTX) have been shown effective in controlling ocular inflammation, preventing AU flares and potential visual loss, and in decreasing the corticosteroids need.^\[[@R11],[@R12]\]^ Nevertheless, patients could be refractory or intolerant to these classical drugs. In recent years, the use of off-label biologic agents, particularly tumor necrosis factor-alpha (TNF-α) inhibitors, has spread worldwide for treatment of patients with noninfectious uveitis resistant to traditional immunosuppressors showing encouraging results.^\[[@R13]\]^ This provides new options for the treatment of AU, which, in turn, calls for the need of updating the evidence in order to establish a framework for supporting treatment recommendations.

Finally, taking also into account that therapeutic decision-making in infectious and malignant AU is much less controversial, the aim of this paper was to perform a systematic and critical review of the literature on the use of immunomodulatory drugs in adult patients with noninfectious and nonmalignant AU.

2. Methods
==========

In context of a clinical practice guideline for the management of uveitis, a systematic literature review (SLR) was performed to address the experts' question on the efficacy and safety of current available immunomodulatory drugs in patients with noninfectious nonmalignant AU. In accordance with the experts, a review protocol was established for this purpose and we followed the indications of the PRISMA statement. As this is an SLR, not an interventional study, an ethical approval was not necessary. The same way patients were not included and therefore informed consent was not given.

2.1. Search strategy
--------------------

The studies were identified by sensitive search strategies in the main medical databases. We have listed the search strategies in the supplementary data. For this purpose, an expert librarian collaborated and checked the search strategies. The following bibliographic databases were screened: Medline (PubMed) and Embase (Embase.com) from 1961 to March 2016, and The Cochrane Library (including Cochrane Central Register of Controlled Trials, i.e., CENTRAL and the Database of Reviews of Effectiveness, i.e., DARE) up to March 2016. We used specific MeSH headings and additional keywords to identify studies on AU and different types of immunomodulatory drugs. The strategy combines disease and treatment terms as listed previously and a controlled vocabulary for describing any of them. All the retrieved references were managed in Endnote X5 (Thomson Reuters).

Finally, a hand search was completed by reviewing the references of the included studies, and all the publications or other information provided by the experts related to SLR were also examined.

2.2. Selection criteria
-----------------------

The studies retrieved by the search strategies were included if they met the following pre-established criteria: Patients had to be diagnosed with active noninfectious nonmalignant AU, 18 years or older, taking an immunomodulatory drug, including SSZ, MTX, cyclosporine A (CsA), azathioprine (AZA), leflunomide, chlorambucil, cyclophosphamide, mycophenolate, and tacrolimus, or biologic therapies (anti-TNFα drugs and others). There was no restriction regarding the type of drug, dose, route of administration, concomitant use of other drugs, or treatment duration. Different outcomes were considered such as control of inflammation, steroid-sparing effect, visual acuity, reduction of the number of uveitis flares, or AE. Only SLR, randomized controlled trials (RCT), or observational studies (study sample size ≥10 patients) were included as well as studies in English, French, or Spanish language. Studies analyzing patients with uveitis from different or various anatomic sites other than anterior segment were excluded unless they performed subanalysis with those with AU.

2.3. Screening of studies, data collection, and data analysis
-------------------------------------------------------------

Screening of studies, data collection, and analysis was performed by 2 reviewers (AG and EL). First, both reviewers screened the titles and abstracts of the retrieved articles for selection criteria independently. This process was done in 20 minutes sessions. If, while doing this, the reviewers found any discrepancy between them, then, a consensus was reached by asking a third reviewer (LC). The same process was afterward undertaken. The articles from the previous selection process were read in detail, and at the end of this phase a list of included studies was established.

The collection of data from the included studies was carried out by two reviewers independently for every article. As in previous processes, in case of discrepancies, a consensus was reached by looking at the original article or by asking the third reviewer (LC). Articles that did not fulfil all the inclusion criteria or that had insufficient data were excluded.

To grade the quality and risk of bias, we used the Jadad score^\[[@R14]\]^ for RCT and a modification of The Oxford Centre for Evidence-based Medicine Levels of Evidence in its May 2011 update,^\[[@R15]\]^ in which articles are classified as follows: systematic reviews of RCT with homogeneity; individual RCT with narrow confidence intervals; trials in which all patients get harm or none does; systematic reviews of cohort studies with homogeneity; individual cohort study, or low quality RCTs; "Outcomes" Research and Ecological studies; systematic reviews of case-control studies with homogeneity; individual case-control study; case-series and poor quality cohort and case-control studies; and expert opinion without explicit critical appraisal, or based on physiology, bench research, or "first principles."

Evidence tables were produced. Descriptive analyses were performed. To describe the included article samples, we used the distribution of frequencies, the mean and standard deviation, or the median and interquartile range, depending on the distribution. Comparisons were performed using the Student *t* test or the chi-square test. Meta-analysis was only planned in case enough homogeneity was present among the included studies.

3. Results
==========

The search strategies retrieved 2166 references (Fig. [1](#F1){ref-type="fig"}), of which 425 were duplicates. After the selection by title and abstract, 98 references were selected for review in detail. After this process, 85 were excluded mainly due to lack of data regarding AU patients or to the absence of a clear anatomic classification of the uveitis (Table [1](#T1){ref-type="table"}).^\[[@R12],[@R13],[@R16]--[@R98]\]^ As a result, 13 articles (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}) were finally included.^\[[@R11],[@R99]--[@R110]\]^ The articles found in the hand search were also excluded.
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The quality of the included articles was in general poor or moderate. We found 2 RCTs,^\[[@R11],[@R105]\]^ the rest were observational studies. Their mean study duration varied from 5 months^\[[@R108]\]^ to 20 years,^\[[@R102]\]^ and the number of AU patients from 9^\[[@R12]\]^ to 274,^\[[@R108]\]^ in whom clinical characteristics were also very heterogeneous (see Table [1](#T1){ref-type="table"}). In most cases, criteria to define the anatomic classification of uveitis and efficacy definitions were not clear. Besides, some of the studies only included AU patients with a systemic disease associated, basically SpA,^\[[@R11],[@R100],[@R102],[@R108],[@R110]\]^ others mixed populations^\[[@R101],[@R104],[@R106]\]^ and in some articles this data was not described (probably idiopathic AU patients).^\[[@R99],[@R103],[@R105],[@R107],[@R109]\]^

AU was treated with different immunomodulatory drugs, including MTX (mean doses from 7.5 to 25 mg/wk),^\[[@R99],[@R103],[@R109]\]^ SSZ (doses from 500 mg to 4 g/d),^\[[@R11],[@R102],[@R106]\]^ AZA 100 mg/d),^\[[@R105],[@R107]\]^ CsA (data regarding doses were not provided)^\[[@R104]\]^ and anti-TNFα drugs, ADA, and golimumab (GLM)^\[[@R100],[@R101],[@R108],[@R110]\]^ following similar doses to those recommended for rheumatologic conditions.

The number of AU flares before and after treatment was the most evaluated outcome along with AU activity and corticosteroids use. However, we found a great variability between studies in the type of outcomes and definitions.

3.1. Methotrexate
-----------------

In patients with idiopathic AU or associated systemic disease, most of them MTX and biologics naïve, MTX significantly decreased the number of AU flares and activity, and increased the time interval between flares (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). MTX doses in these patients ranged from 7.5 to 25 mg/wk and this effect was described in the short and long term. In the subgroup of patients taking systemic corticosteroids at baseline, the dose of these drugs was progressively tapered until discontinuation in many of them.^\[[@R99],[@R103]\]^ One study also depicted the same results regardless of HLA-B27 status (positive or negative).^\[[@R99]\]^ Reported AEs were the same as those previously described for MTX.

3.2. Salazopyrin
----------------

SSZ (from 500 mg to 2 g/d for 3 years) was evaluated in a low-quality RCT^\[[@R11]\]^ that revealed a significant reduction in the number of AU flares and an improvement in visual acuity of those patients diagnosed with ankylosing spondylitis (AS)-associated AU. No relevant AEs were recorded. In other observational studies, a decrease of UA flares was also observed, without relevant AEs.^\[[@R102],[@R106]\]^ SSZ has been primarily used in idiopathic and AS/SpA-associated AU.

3.3. Azathioprine
-----------------

A 3-months RCT published in 1969 compared AZA (100 mg/d) with placebo in 16 patients with AU. The authors did not find differences in visual acuity, number of anterior chamber cells, AU flares, or intraocular pressure after 3 months of treatment.^\[[@R105]\]^ Another prospective study analyzed the effect of AZA in AU patients of whom 24% were refractory to other immunomodulators.^\[[@R107]\]^ AZA significantly improved ocular inflammation and decreased systemic corticosteroids doses. At 6 months and 1 year, 24% and 35% of patients, respectively, showed no ocular activity. AEs were the same as those usually registered for this drug.

3.4. Cyclosporine A
-------------------

Regarding CsA, in a moderate quality observational study,^\[[@R104]\]^ that included AU patients (almost 75% with a systemic disease-associated AU), 33% by 6 months and 51% by 1 year gained sustained and complete control of inflammation over at least 2 visits spanning at least 28 days. Besides, a steroid-sparing success was achieved by 22.1% by 6 months and 36.1% within 1 year. The most frequent AE in this study was renal toxicity.

3.5. Anti-TNFα agents
---------------------

We included 3 articles reporting the outcomes of adalimumab (ADA) in AU. All were observational studies in which the majority of participants were SpA-associated AU patients (up to 40% refractory to other anti-TNFα agents). In this population, ADA improved different outcomes, including the number of AU flares, ocular inflammation, and dose of corticosteroids. This effect remained in the long term.^\[[@R101],[@R108],[@R109]\]^ One of these studies also showed that the rate of AU flares was reduced by 51% in all study patients, by 58% in 274 patients with a history of AU, by 68% in 106 patients with a recent history of AU, and by 50% in 28 patients with symptomatic AU at baseline. AU flares during ADA treatment in this work were predominantly mild.^\[[@R108]\]^ Expected AE were registered in all studies.

Two more reports analyzing GLM in patients with AU, refractory to immunomodulators including biologic therapies in many patients were included.^\[[@R100],[@R110]\]^ Both studies analyzed a total of 27 patients with SpA-associated AU. The first one depicted a significant improvement in visual acuity, number of UA flares, and need of systemic steroids during a mean follow-up of almost 1 year.^\[[@R110]\]^ On the other hand, 1 patient developed a malignant hypertension and stopped GLM. In the second one, most patients had rapid and progressive improvement in visual acuity and inflammatory parameters as well as in the steroid need. The number of AU flares also decreased but this difference was nonsignificant. In this study, 87% of patients also reached clinical remission after a median follow-up of 23 months.^\[[@R100]\]^

4. Discussion
=============

We have performed an SLR to analyze the efficacy and safety of immunomodulators when used for treatment of adult patients with noninfectious and nonmalignant AU. To our knowledge, this is the first one specifically designed to analyze patients with AU.

Currently, there is a lack of robust evidence in clinical practice regarding the use of immunomodulators in these patients. Even with this limitation, there is some evidence supporting the use of MTX, SSZ, AZA, CsA, ADA, and GLM.

More specifically, as first line immunomodulators, but also in patients resistant to other immunosuppressive agents, MTX, SSZ, and CsA have shown effectiveness to prevent AU flares, improve visual acuity, and to decrease systemic steroids dose in the short and the long term (up to 3 years). These results have been described in patients with idiopathic AU and patients with an associated systemic disease. In the case of AZA, this drug could also be effective in improving ocular inflammation and in reducing systemic corticosteroids need, in patients who are naïve or refractory to other immunomodulators. This effect has been depicted in the short and long term as well. On the other hand, the evidence also supports the use of ADA and GLM, in different clinical aspects of AU (including refractory patients to other immunomodulators), as they have improved outcomes of interest including AU flares, degree of ocular inflammation, and the need for corticosteroids treatment. In addition, we have evidence of immunomodulators' benefit in the short and the long term. Besides, the AEs reported did not differ from those reported when used these drugs for treatment of other immune-mediated conditions.^\[[@R111]\]^

As commented before, regarding the study populations, the included studies analyzed patients with idiopathic AU and patients with an associated systemic disease in whom immunomodulators achieved a good response in many of them. In the case of patients with an associated systemic disease, most of them were SpA patients, especially AS, but the studies also included patients with other types of SpA like psoriatic arthritis. Moreover, 1 study found that MTX improved outcomes in both, HLA-B27 positive and negative patients.^\[[@R99]\]^ In this article, although the rate of flares decreased, all the observed flares occurred in the HLA-B27 positive patients.

The selection criteria of the immunomodulators were not described in detail. Classical immunomodulators were used as first-line agents in patients with inadequate response to topical treatments and/or systemic corticosteroids, but also in refractory patients to other immunomodulators, as depicted for anti-TNFα therapies. Doses and routes of administration were those recommended in the summary of products characteristics, and almost 100% of treatments with immunomodulatory drugs were used in monotherapy. Unfortunately there were no comparative studies between immunomodulators.

The main limitation of this SLR is the quality of the included studies that was quite poor in general, limiting the generalization of conclusions. This lack of robust evidence probably, at least in part, might have been solved in daily practice using the evidence and experience from other chronic immune-mediated diseases. Another of the main limitations of the SLR is the lack of proper standardization of the uveitis anatomic classification and definition of outcomes. Therefore, we excluded many articles that actually analyzed patients with AU but did not perform subanalysis of patients with AU. The same way comparisons between studies results were very complicated and a meta-analysis was not possible.

Interestingly, we did not include any article with other biologics like infliximab or tocilizumab. We found some reports during the selection process but eventually excluded them because they did not meet the inclusion criteria, mainly due to lack of subanalysis or due to the sample size of the studies. However, in the literature there are some case series suggesting that these drugs could be effective as those reported with ADA or GLM.^\[[@R112]--[@R114]\]^ In the case of etanercept, observational reports have indicated lower effectiveness and some paradoxical occurrence of uveitis following treatment with this agent.^\[[@R115]\]^

In summary, even with all the limitations exposed previously, immunomodulators could be effective in patients with noninfectious and nonmalignant AU in order to prevent flares and improve other ocular outcomes. However, more research is needed in order to properly define the role of each immunomodulator in this population.

Abbreviations: ADA = adalimumab, AE = adverse events, AS = ankylosing spondylitis, AU = anterior uveitis, AZA = azathioprine, CsA = cyclosporine A, GLM = golimumab, g = gram, mg = milligram, MTX = methotrexate, RCT = randomized controlled trials, SLR = systematic literature review, SpA = spondyloarthritis, SSZ = salazopyrin, TNF-α = tumor necrosis factor-alpha.
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